Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Sabine Gruener

Guy Georges

Olaf Mundigl

Stefan Dengl

Guido Hartmann

Peter Michael Huelsmann

Christian Gassner

Sebastian Breuer

Joerg Thomas Regula

Ralf Schumacher

Joerg Moelleken

Barbara Weiser

Marc Bedoucha

Matthias Heinrich Nettekoven

Stephan Roever

Paul Hebeisen

Hubert Kettenberger

Michael Molhoj

Christoph Ullmer

Bernd Puellmann

Michel Dietz

Sylvie C Meyer Reigner

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Bispecific antibodies and methods of use in ophthalmology

Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.

Anti-IL-1beta antibodies

Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.

Anti-PDGF-B antibodies and methods of use

The present invention relates to compounds of the formula wherein Rto Rare as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CBreceptors.

Pyrazine-2-carboxamide derivatives as CB2 receptor modulators

Growing community of inventors

Grenzach-Wyhlen, Germany

Sabine Gruener